• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Our Products
    • Restoret
  • Team
EyeBio

EyeBio

  • Business Development
  • News
  • Contact

Back to Home

Expanded Access Policy

Patients may want to access our experimental medicines outside of clinical trials.  Such access is called “Expanded Access” (sometimes called “compassionate use”).  We recognize the value of Expanded Access; however, at this time EyeBio is not accepting any requests for Expanded Access.  Our lead drug, EYE103, is in the early stages of clinical studies and we are still gathering evidence from these studies. As our studies progress, we may re-evaluate this Expanded Access policy.  If our policy changes, we will endeavor to update this page accordingly. 

For questions please contact us here.  We anticipate we will need 10 working days to acknowledge receipt of such requests.

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Expanded Access Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Our Products
    • Restoret
  • Team
  • Business Development
  • News
  • Contact